Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3725259 | 0.94 | EPHX1 (0.30) | EPHX1 | |
| SCHEMBL4612910 | 0.81 | GRM2 (0.32) | — | |
| SCHEMBL1015563 | 0.72 | — | — | |
| SCHEMBL1466657 | 0.72 | — | — | |
| SCHEMBL21380220 | 0.72 | DGAT1 (0.38) | — | |
| SCHEMBL23795633 | 0.71 | — | — | |
| SCHEMBL20798271 | 0.67 | EPHX1 (0.31) | EPHX1 | |
| SCHEMBL3417762 | 0.67 | HSD11B1 (0.33) | — | |
| SCHEMBL7095245 | 0.66 | — | — | |
| SCHEMBL16060705 | 0.66 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2158198-A2 | NOVEL N- (8HETEROARYLTETRAHYDRONAPHTALENE-2YL) OR N- (5- HETEROARYLCHROMANE-3-YL) CARBOXAMIDE DERIVATIVES FOR THE TREATMENT OF PAIN | AstraZeneca AB (SE) | 2010-03-03 | — | — | EP | claimed |
| WO-2008130320-A2 | NOVEL N- (8-HETEROARYLTETRAHYDRONAPHTALENE-2YL) OR N- (5- HETEROARYLCHROMANE-3-YL) CARBOXAMIDE DERIVATIVES FOR THE TREATMENT OF PAIN | ASTRAZENECA AB (SE) | 2008-10-30 | — | — | WO | claimed |
| EP-1937639-A2 | PYRIDINAMINOSULFONYL SUBSTITUTED BENZAMIDES AS INHIBITORS OF CYTOCHROME P450 3A4 (CYP3A4) | Pfizer Products Incorporated (US) | 2008-07-02 | — | — | EP | claimed |
| WO-2007034312-A2 | PYRIDINAMINOSULFONYL SUBSTITUTED BENZAMIDES AS INHIBITORS OF CYTOCHROME P450 3A4 (CYP3A4) | PFIZER PRODUCTS INC. (US) | 2007-03-29 | — | — | WO | claimed |
| EP-4499097-A1 | METHODS OF TREATING A SUBJECT FOR POST-TREATMENT LYME DISEASE (PTLD) AND COMPOSITIONS FOR USE IN THE SAME | IncellDx, Inc. (US) | 2025-02-05 | — | — | EP | disclosed |
| WO-2023192360-A1 | METHODS OF TREATING A SUBJECT FOR POST-TREATMENT LYME DISEASE (PTLD) AND COMPOSITIONS FOR USE IN THE SAME | INCELLDX, INC. (US) | 2023-10-05 | — | — | WO | disclosed |
| EP-2158198-A2 | NOVEL N- (8HETEROARYLTETRAHYDRONAPHTALENE-2YL) OR N- (5- HETEROARYLCHROMANE-3-YL) CARBOXAMIDE DERIVATIVES FOR THE TREATMENT OF PAIN | AstraZeneca AB (SE) | 2010-03-03 | — | — | EP | disclosed |
| WO-2008130320-A2 | NOVEL N- (8-HETEROARYLTETRAHYDRONAPHTALENE-2YL) OR N- (5- HETEROARYLCHROMANE-3-YL) CARBOXAMIDE DERIVATIVES FOR THE TREATMENT OF PAIN | ASTRAZENECA AB (SE) | 2008-10-30 | — | — | WO | disclosed |
| US-7405229-B2 | Cathepsin cysteine protease inhibitors | MERCK FROSST CANADA & CO. (CA) | 2008-07-29 | — | — | US | disclosed |
| US-20070167635-A1 | Cathepsin cysteine protease inhibitors | MERCK CANADA INC. (CA) | 2007-07-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070167635-A1 | Cathepsin cysteine protease inhibitors | CTSB, CTSS, CTSK | EPHX1 2614/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.